Welcome
Support Centre
25 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Aspirin and simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes
ISRCTN ISRCTN48110081
DOI 10.1186/ISRCTN48110081
ClinicalTrials.gov identifier
EudraCT number
Public title Aspirin and simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes
Scientific title A randomised study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
Acronym ACCEPT-D
Serial number at source FARM57W8MN
Study hypothesis To assess the effects of low dose aspirin on the incidence of major vascular events, in a wide range of people with type one or type two diabetes with no clinical evidence of vascular disease and receiving statins treatment.

Please note that as of 11/02/2009 this record was updated to include amended trial dates. The initial trial dates at the time of registration were:
Initial anticipated start date: 12/03/2007
Initial anticipated end date: 12/09/2013
Lay summary
Ethics approval Added 11/02/2009: Ethics Committee of the A.S.O. San Luigi Gonzaga, Orbassano (Italy) gave approval on the 2nd April 2007 (ref: 8143)
Study design Open-label randomised parallel-group study
Countries of recruitment Italy
Disease/condition/study domain Type one and two diabetes mellitus
Participants - inclusion criteria 1. Written informed consent to participate in this study
2. Clinical diagnosis of type one or type two diabetes, irrespective of diabetes treatment
3. Need for statin treatment:
3.1. Patients already receiving statin therapy irrespective of their actual low density lipoprotein (LDL) cholesterol and total cholesterol levels, or
3.2. Patients not currently on statin treatment with LDL cholesterol levels more than or equal to 110 mg/dL persisting after three months of dietary advice
4. Ability and willingness to comply with all study requirements
5. Male and female subjects aged greater than or equal to 50 years
Participants - exclusion criteria 1. Previous major vascular events (non-fatal myocardial infarction, non-fatal stroke, angina, transient ischaemic attack, revascularisation procedures, peripheral vascular disease)
2. Unstable metabolic control (HbA1c more than 14.0%)
3. Any condition requiring elective treatment with aspirin
4. Contraindications to aspirin
5. Contraindications to simvastatin
6. Chronic therapy with non-steroidal anti-inflammatory drugs (NSAIDs)
7. Presence of any life-threatening condition
8. Child-bearing potential (pre-menopausal women not using reliable contraception)
9. History of active substance or alcohol abuse within the last year
Anticipated start date 22/10/2007
Anticipated end date 30/04/2015
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 5170
Interventions Treatment arm: aspirin 100 mg/day per os (orally) until the achievement of the pre-established number of cardiovascular events (515 events; about five years)
Control arm: no aspirin given
Primary outcome measure(s) To assess the effects of low dose aspirin on the incidence of major vascular events (defined as a combined end-point of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or inpatient or outpatient hospital admission for cardiovascular causes, including acute coronary syndrome, not planned revascularisation procedures, peripheral vascular disease), in a wide range of people with type one or type two diabetes with no clinical evidence of vascular disease and receiving statins treatment.
Secondary outcome measure(s) 1. Total and cause specific mortality
2. Venous thromboembolic episodes
3. Major haemorrhagic episodes
4. Total number of hospitalisations for cardiovascular causes (myocardial infarction, stroke, acute coronary syndrome, not planned revascularisation procedures, heart failure, transient ischaemic attack, peripheral vascular disease, lower limb revascularisation procedures)
Sources of funding Italian Ministry of Health (Italy) - public funding grant received
Trial website
Publications Study protocol on http://www.ncbi.nlm.nih.gov/pubmed/17725825
Contact name Dr  Antonio  Nicolucci
  Address Department of Clinical Pharmacology and Epidemiology
Consorzio Mario Negri Sud
Via Nazionale, 8/a
  City/town S. Maria Imbaro
  Zip/Postcode 66030
  Country Italy
Sponsor Consortium Mario Negri South (Consorzio Mario Negri Sud) (Italy)
  Address Via Nazionale, 8/a
  City/town S. Maria Imbaro
  Zip/Postcode 66030
  Country Italy
  Tel +39 (0)872 570260
  Fax +39 (0)872 570263
  Email accept-d@negrisud.it
  Sponsor website: http://www.negrisud.it
Date applied 18/01/2007
Last edited 11/02/2009
Date ISRCTN assigned 05/03/2007
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.